Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th- rituximab

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 1, 2010, Pages 93-102

  Dahle, Jostein ^a   Jonasdottir, Thora J ^b   Heyerdahl, Helen ^a   Nesland, Jahn M ^a,c   Borrebæk, Jørgen ^d   Hjelmerud, Anne Kristine ^a   Larsen, Roy H ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Algeta AS   (Norway)

Author keywords

Bone marrow; Low dose rate alpha radiation; Radioimmunotherapy; Radiotoxicity; Rituximab; Thorium

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BILE ACID; RITUXIMAB; RITUXIMAB THORIUM TH 227; THORIUM; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAGG ALBINO MOUSE; BILE ACID BLOOD LEVEL; BODY WEIGHT; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; LEUKOCYTE COUNT; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; RADIATION INJURY; THROMBOCYTE COUNT; TUMOR XENOGRAFT;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; IMMUNOCONJUGATES; LONGITUDINAL STUDIES; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIATION DOSAGE; RADIATION INJURIES; RADIOPHARMACEUTICALS; THORIUM; TREATMENT OUTCOME;

EID: 72949096312     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1197-7     Document Type: Article

References (26)

1. Hall EJ. Radiobiology for the radiologist. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
2. G Henriksen OS Bruland RH Larsen 2004 Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents Anticancer Res 24 101 105 1:CAS:528:DC%2BD2cXisFGnur4%3D 15015582
3. J Dahle J Borrebaek KB Melhus OS Bruland G Salberg DR Olsen, et al. 2006 Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy Nucl Med Biol 33 271 279 10.1016/j.nucmedbio. 2005.12.004 1:CAS:528:DC%2BD28Xis1ehtr4%3D 16546683
4. J Dahle J Borrebaek TJ Jonasdottir AK Hjelmerud KB Melhus ∅S Bruland, et al. 2007 Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate Blood 110 2049 2056 10.1182/blood-2007-01- 066803 1:CAS:528:DC%2BD2sXhtVGjtbbM 17536011 (Pubitemid 47443922)
5. JS Jaggi SV Seshan MR McDevitt K LaPerle G Sgouros DA Scheinberg 2005 Renal tubulointerstitial changes after internal Irradiation with alpha-particle-emitting actinium daughters J Am Soc Nephrol 16 2677 2689 10.1681/ASN.2004110945 1:CAS:528:DC%2BD2MXhtFeisLrJ 15987754
6. G Henriksen K Breistøl S Bruland Fodstad RH Larsen 2002 Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model Cancer Res 62 3120 3125 1:CAS:528:DC%2BD38XksVyqsrY%3D 12036923
7. G Henriksen DR Fisher JC Roeske S Bruland RH Larsen 2003 Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice J Nucl Med 44 252 259 1:CAS:528:DC%2BD3sXhsFygsL4%3D 12571218
8. S Nilsson RH Larsen SD Fosså L Balteskard KW Borch JE Westlin, et al. 2005 First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 4451 4459 10.1158/1078-0432.CCR-04-2244 1:CAS:528:DC%2BD2MXltFeksrc%3D 15958630 (Pubitemid 40834252)
9. KB Melhus RH Larsen T Stokke O Kaalhus PK Selbo J Dahle 2007 Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th Cancer Biother Radiopharm 22 469 479 10.1089/cbr.2007.371 1:CAS:528:DC%2BD2sXpvFWmsbc%3D 17803441 (Pubitemid 47403467)
10. RH Larsen H Saxtorph M Skydsgaard J Borrebaek TJ Jonasdottir OS Bruland, et al. 2006 Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology In Vivo 20 325 331 1:CAS:528:DC%2BD28XlvVWiu7Y%3D 16724665
11. S Nilsson L Franzén C Parker C Tyrrell R Blom J Tennvall, et al. 2007 Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 587 594 10.1016/S1470-2045(07)70147-X 1:CAS:528:DC%2BD2sXnsFKkurw%3D 17544845 (Pubitemid 46995621)
12. J Elgqvist P Bernhardt R Hultborn H Jensen B Karlsson S Lindegren, et al. 2005 Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice J Nucl Med 46 464 471 1:CAS:528:DC%2BD2MXivVCgurs%3D 15750160
13. RE McLendon GE Archer RH Larsen G Akabani DD Bigner MR Zalutsky 1999 Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis Int J Radiat Oncol Biol Phys 45 491 499 1:CAS:528:DyaK1MXls12ntbs%3D 10487576
14. MR Zalutsky MG Stabin RH Larsen DD Bigner 1997 Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate Nucl Med Biol 24 255 261 10.1016/S0969-8051(97)00060-7 1:CAS:528:DyaK2sXktlOqu7o%3D 9228660 (Pubitemid 27293470)
15. TM Behr G Sgouros MG Stabin M Béhé C Angerstein RD Blumenthal, et al. 1999 Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters Clin Cancer Res 5 3031s 3043s 1:CAS:528: DyaK1MXnsVShsb0%3D 10541340
16. RH Larsen J Borrebaek J Dahle KB Melhus C Krogh MH Valan, et al. 2007 Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability Cancer Biother Radiopharm 22 431 437 10.1089/cbr.2006.321 1:CAS:528:DC%2BD2sXotFygtr8%3D 17651051 (Pubitemid 47067902)
17. T Lindmo PA Bunn Jr 1986 Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling Methods Enzymol 121 678 691 10.1016/0076-6879(86)21067-8 1:CAS:528:DyaL28XlsFWjt7Y%3D 3523136
18. LM Ashmore GM Shopp BS Edwards 1989 Lymphocyte subset analysis by flow cytometry. Comparison of three different staining techniques and effects of blood storage J Immunol Methods 118 209 215 10.1016/0022-1759(89)90008-2 1:STN:280:DyaL1M7ns1eisA%3D%3D 2466904 (Pubitemid 19082048)
19. MA Dorato JA Engelhardt 2005 The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s) Regul Toxicol Pharmacol 42 265 274 10.1016/j.yrtph.2005.05.004 1:CAS:528:DC%2BD2MXmvVCgt7k%3D 15979222 (Pubitemid 41021976)
20. M Miederer MR McDevitt G Sgouros K Kramer NK Cheung DA Scheinberg 2004 Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates J Nucl Med 45 129 137 1:CAS:528: DC%2BD2cXht1artbY%3D 14734685
21. J Dahle OS Bruland RH Larsen 2008 Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation Int J Radiat Oncol Biol Phys 72 186 192 1:CAS:528:DC%2BD1cXhtVamu7zK 18722269
22. TM Behr M Béhé G Sgouros 2002 Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings Cancer Biother Radiopharm 17 445 464 10.1089/108497802760363231 1:CAS:528:DC%2BD38Xot1Ggt7w%3D 12396708
23. RW Howell MT Azure VR Narra DV Rao 1994 Relative biological effectiveness of alpha-particle emitters in vivo at low doses Radiat Res 137 352 360 10.2307/3578710 1:CAS:528:DyaK2cXitFWmtLY%3D 8146279
24. RW Howell SM Goddu VR Narra DR Fisher RE Schenter DV Rao 1997 Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo Radiat Res 147 342 348 10.2307/3579342 1:CAS:528:DyaK2sXhvV2js7o%3D 9052681 (Pubitemid 27114391)
25. BA Muggenburg FF Hahn WC Griffith Jr RD Lloyd BB Boecker 1996 The biological effects of radium-224 injected into dogs Radiat Res 146 171 186 10.2307/3579589 1:CAS:528:DyaK28XkvFCqsLg%3D 8693067
26. Moore DM. Hematology of the mouse (Mus musculus). In: Feldman BF, Zinkl JG, Jain NC, editors. Chalm's veterinary hematology. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 1219-24.